Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/3980| Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic | |
| Scuccimarri Rosie. Sutton Evelyn. Fitzcharles Mary-Ann. | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| 10.3899/jrheum.200369 | |
| Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past seventy years [1]. These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of coronavirus (SARS-CoV2) associated disease called COVID-19 [2, 3]. | |
| The Journal of Rheumatology | |
| 2020 | |
| Artículo | |
| http://www.jrheum.org/content/jrheum/early/2020/04/01/jrheum.200369.full.pdf | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| 1105591.pdf | 1.73 MB | Adobe PDF | Visualizar/Abrir |